Guillain-Barré syndrome after exogenous gangliosides in Italy.

G Landi, R. D’Alessandro, B. Currò Dossi, Susanna Ricci, Isabella Laura Simone, Alfonso Ciccone

BMJ · 1993 · 48 citations · 5 references

DOIFull text

Open access

Concepts

Abstract

Exogenous gangliosides are marketed in several countries and used to treat many neurological diseases. Although no well designed clinical trial has con- vincingly shown their efficacy in diseases of the peripheral or central nervous system, they are widely prescribed, at least in Italy. An estimated 4-1% of the population in Rome were prescribed gangliosides in 1989,1 and in 1991 around 4-2% of the 687 401 people from five local health districts in the Emilia Romagna region received the drugs (N Montanaro, et al, personal communication).

References

5